kyron.bio

kyron.bio is a Paris-based biotechnology company pioneering precision glycoengineering to enhance the efficacy, safety, and scalability of antibody therapeutics. Founded in 2022, the company leverages a proprietary platform that combines engineered Chinese Hamster Ovary (CHO) cell lines with structure-guided design to achieve over 97% consistency in N-glycan structures. This technology addresses critical challenges in biologics development, such as immunogenicity and variable therapeutic performance, by transforming glycans into a precise design tool. kyron.bio operates through strategic drug design partnerships, including a notable collaboration with Servier, while also developing its own internal pipeline of next-generation therapeutics for oncology and autoimmune diseases.